Dr. Wissink joined Regulatory Affairs Europe MSD in January 2014 to lead the company’s oncology efforts, including the registration of the PD-1 inhibitor, Keytruda® as well as its developmental activities. Prior to joining Regulatory Affairs Europe, Dr. Wissink was Director, Global Regulatory Affairs at MSD responsible for Alzheimer’s Disease development. Dr Wissink started her career in Industry in Regulatory Affairs in Organon in 1999, and held different positions of increasing responsibility within Organon, Schering-Plough and MSD. Dr. Wissink received her PhD in Molecular Biology from the University of Utrecht. Prior to joining industry, she held the position of Postdoctoral Fellow at the Hubrecht institute, Utrecht, the Netherlands.